AbCellera says its phase two ABCL635 hot flash trial showed roughly twice the frequency reduction of small-molecule NK3R antagonists at four weeks; 12-week data is due early 2027.
ABCL · AbCellera Biologics Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
AbCellera Biologics Inc. said ABCL635 achieved twice the frequency and four to five times the severity efficacy of approved small molecules, with a clean safety profile supporting planned late-stage development.
ABCL said its ABCL 635 produced a 50% placebo-controlled hot-flash reduction in a 92-patient trial, with a clean safety profile and evidence supporting once monthly dosing, and is preparing for late stage development.
ABCL635 showed a 50% placebo-adjusted reduction in moderate-to-severe hot-flash frequency in Phase 2. Abcelera plans late-stage development in 2027, raised $200 million, and ended the quarter with over $790 million in cash and marketable securities.
AbCellera reported that ABCL635 met primary Phase 2 efficacy endpoints, with a 5.3 placebo-adjusted treatment difference in daily moderate and severe hot flashes (p<0.001), and plans late-stage development in 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 9, 2026TL;DR. ABCL635 delivered strong Phase 2 efficacy and favorable tolerability, with 2027 development plans, a $200 million capital raise, an expanded pipeline, and over $890 million of available liquidity. ABCL575 will stop after Phase 1, ABCL635 efficacy is expected to decline during washout, the partner-program count fell from 44 to 34, and nine-month revenue and net loss worsened versus the prior-year period.
- − Although ABCL575 met its Phase 1 endpoints with favorable tolerability and pharmacokinetics, AbCellera does not plan to develop it beyond Phase 1. new
- − ABCL635 efficacy is expected to decline during the final eight-week washout, and the company does not expect efficacy to be maintained through 12 weeks after a single dose. new
- − The number of partner-led programs believed to be progressing and in which AbCellera holds a downstream stake fell to 34 from 44 at December 31, 2025. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| available liquidity to execute on our strategy | $790M | As of September 30, 2026 | — |
| Available non-dilutive government funding | $100M | Q3 2026 | — |
| Complete resolution of VMSM-S | 37% | Week 4 (data cutoff 30JUL26) | — |
| Molecules in the clinic with downstream stakes | 12 | September 30, 2026 | — |
| Partner-led programs with downstream stake | 34 | End of Q3 2026 (September 30, 2026) | — |
|
|
|||
| Total available liquidity | $890M | Q3 2026 | — |
|
|
|||
| total cash balances & marketable securities | $100M | As of September 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ABCL
this stock
AbCellera Biologics Inc.
|
$3.60B | +222.2% | +160.6% | — | 8.9% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 26
AbCellera says its phase two ABCL635 hot flash trial showed roughly twice the frequency reduction of small-molecule NK3R antagonists at four weeks; 12-week data is due early 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ABCL | -7.8% | -10.0% | +78.6% | -10.2% | +222.2% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -3.9% | -4.4% | +82.1% | -6.8% | +215.1% |